On October 20, 2023, the board of directors of Quince Therapeutics, Inc. appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition. Mr. Benatti was designated as a Class II director whose term expires at the Company?s 2024 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.854 USD | +1.67% | -4.04% | -18.67% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.67% | 37.17M | |
+48.67% | 56.69B | |
-2.76% | 41B | |
+36.42% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Appoints Luca Benatti as Director